Le Lézard
Classified in: Science and technology
Subjects: Survey, Webcast

Cymulate Releases Findings from Over One Million Security Assessments and 1.7 Million Hours of Testing


Cymulate, the leader in cybersecurity risk validation and exposure management, today released the company's "2022 Cybersecurity Effectiveness Report" which analyzed the results of over a million security posture validation assessments, including 1.7 million hours of offensive cybersecurity testing within Cymulate's production environments.

The report provides critical insights in global cybersecurity effectiveness, critical findings and top attack tactics, techniques, and procedures (TTPs). The report delves into the efficacy of different security controls, the most concerning threats as tested by organizations worldwide, and top cybersecurity best practices for 2023.

Report key takeaways include:

When comparing the anonymized data between the first Endpoint Security assessment completed and the most recent assessments completed, significant improvements in risk reduction were seen when BAS testing was regularly performed. The improvements were seen consistently across customers of various industries and sizes.

"It's understandable that organizations want to protect themselves against the major threats making headlines today," said Carolyn Crandall, Chief Security Advocate for Cymulate. "But the findings of the Cybersecurity Effectiveness Report underscore the fact that many attackers aren't using advanced new strategies?they're continuing to find success using known tactics. Organizations need to shift their vulnerability management strategies to address these gaps by implementing Attack Surface Management tools for exposure assessment, Breach and Attack Simulation for security control efficacy validation, and Continuous Automated Red Teaming for more frequent penetration testing."

"Organizations must understand their security posture to identify vulnerabilities and protect against cyber threats," said David Neuman, senior analyst at TAG Cyber. "Cymulate's release of findings from over one million security assessments and 1.7 million hours of testing provides valuable insights into common weaknesses and areas for improvement in cybersecurity. This data highlights the need for continuous security testing and risk assessments to stay ahead of emerging threats."

The full Cymulate 2023 Cybersecurity Effectiveness Report can be found here. Register for a webinar of the findings here.

About Cymulate

The Cymulate cybersecurity risk validation and exposure management solution provides security professionals with the ability to continuously challenge, validate and optimize their on-premises and cloud cyber-security posture with end-to-end visualization across the MITRE ATT&CK® framework. The platform provides automated, expert, and threat intelligence-led risk assessments that are simple to deploy, and easy for organizations of all cybersecurity maturity levels to use. It also provides an open framework for creating and automating red and purple teaming exercises by generating tailored penetration scenarios and advanced attack campaigns for their unique environments and security policies. For more information, visit www.cymulate.com.


These press releases may also interest you

at 02:17
Fun88, a leading company in sports and entertainment, proudly announces its official title sponsorship with the Vizag Warriors for the Andhra Premier League (APL)....

at 02:10
KLab Inc., a leader in online mobile games, announced that its hit 3D action game Bleach: Brave Souls will be holding a Bleach: Brave Souls 9th Anniversary Bankai Live! on Sunday, July 14, 2024 from 18:30 (JST/UTC+9). See the original press release...

at 02:00
Azentio Software ("Azentio") - a leading end-to-end software company specializing in the BFSI sector, today announced the appointment of Aarthi Ramesh as Chief Customer Officer and Emma Foley as Chief Marketing Officer....

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

at 01:05
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Bel Group, today announced their long-term partnership to accelerate the food industry's transformation toward a more sustainable model. The companies will play a pivotal role in shaping...



News published on and distributed by: